Hormone therapy and intraocular pressure in nonglaucomatous eyes

Tint, Naing L.; Alexander, Philip; Tint, Khin M; Vasileiadis, George T; Yeung, Aaron M.; Azuara‐Blanco, Augusto

doi:10.1097/gme.0b013e3181b82fb4

Cited by 45 publications

(36 citation statements)

References 17 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, PMH use may help reduce the risk for POAG (18). Clinical studies have shown hormone therapy supplementation to be associated with modest reduction in IOP as well as some evidence supporting a potential protective effect on RGCs (4, 19–24). …”

Section: Discussionmentioning

confidence: 99%

Oral Contraceptive Use and Prevalence of Self-Reported Glaucoma or Ocular Hypertension in the United States

et al. 2016

View full text Add to dashboard Cite

Objective To investigate the association between oral contraceptive (OC) use and glaucoma prevalence in the United States. Design Cross-sectional study. Participants 3406 female participants, 40 years of age or older, from the 2005–2008 National Health and Nutrition Examination Survey, who reported a presence or absence of glaucoma or ocular hypertension, completed both the vision and reproductive health questionnaires and underwent eye examinations. Methods Multivariate regression analysis was used to assess the correlation between OC use and self-reported glaucoma or ocular hypertension (n=231 cases), controlling for potential confounders including age, ethnicity, systemic comorbidities such as hypertension and stroke, ocular diseases such as cataract and diabetic retinopathy, reproductive health factors including age at menopause, age at menarche, history of hormone replacement therapy and gynecological surgical history. Main Outcome Measures The outcome variable was self-reported glaucoma or ocular hypertension. Results After adjusting for confounders, those with ≥3 years of OC use had greater odds (odds ratio= 1.94, 95% confidence interval=1.22–3.07) of self-reported glaucoma or ocular hypertension. Other factors associated with higher glaucoma or ocular hypertension prevalence included older age, African American race, and later age of menarche. Conclusion OC use may be associated with increased risk of self-reported glaucoma or ocular hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral Contraceptive Use and Prevalence of Self-Reported Glaucoma or Ocular Hypertension in the United States

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Some report no effect of hormone therapy on IOP (Guaschino et al 2003, Abramov et al 2005, and one study (Khurana et al 2006) found that HRT raises IOP in postmenopausal females with dry eye syndrome. However, most studies observed that hormone therapy significantly lowers IOP in menopausal (Sator et al 1998) and postmenopausal women (Guaschino et al 2003, Altintas et al 2004, Uncu et al 2006, Tint et al 2010, Coksuer et al 2011; data given in Table 1). This conclusion is supported by animal models, where it has been reported that E 2 prevents retinal ganglion cell loss induced by acute IOP elevation in rats (Russo et al 2008).…”

Section: Eye Disease and The Retinamentioning

confidence: 99%

Oestrogen, ocular function and low-level vision: a review

Hutchinson¹,

Walker²,

Davidson³

2014

Journal of Endocrinology

View full text Add to dashboard Cite

Over the past 10 years, a literature has emerged concerning the sex steroid hormone oestrogen and its role in human vision. Herein, we review evidence that oestrogen (oestradiol) levels may significantly affect ocular function and low-level vision, particularly in older females. In doing so, we have examined a number of vision-related disorders including dry eye, cataract, increased intraocular pressure, glaucoma, age-related macular degeneration and Leber's hereditary optic neuropathy. In each case, we have found oestrogen, or lack thereof, to have a role. We have also included discussion of how oestrogen-related pharmacological treatments for menopause and breast cancer can impact the pathology of the eye and a number of psychophysical aspects of vision. Finally, we have reviewed oestrogen's pharmacology and suggest potential mechanisms underlying its beneficial effects, with particular emphasis on anti-apoptotic and vascular effects.

show abstract

“…22 A consequence of this is raised IOP within the eye, as demonstrated by a study of postmenopausal women which found that IOP in women on hormone replacement therapy was 1.41 mmHg lower than in those not on hormone replacement therapy. 23 This rise in IOP, combined with increased susceptibility of the optic nerve resulting from the absence of circulating estrogens, may contribute to the development of glaucoma in post-menopausal women.…”

Section: Discussionmentioning

confidence: 99%